Wegovy Tops Sibling Saxenda for Weight Loss

A study showing that once-weekly subcutaneous semaglutide 2.4 mg (Wegovy, Novo Nordisk) produces greater long-term weight loss than once-daily injected

Read more

New Index Aims to Clarify Type 1 Diabetes Burden Worldwide

A new online tool will reflect the burden of type 1 diabetes in every country around the world, with the

Read more

Screen More, Personalize, Use Technology

The American Diabetes Association’s updated clinical recommendations for 2022 call for wider population screening, along with furthering the trends towards

Read more